ACETO Subsidiary, Rising Pharmaceuticals, to Launch Oxybutynin Chloride Extended-Release Tablets, USP
Rising Pharmaceuticals, Inc. | February 03, 2017
ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Oxybutynin Chloride Extended-Release Tablets, USP, an FDA-approved generic version of Janssen Pharmaceuticals, Inc.’s Ditropan XL Tablets.